Company profile VOR
After 38 days of this quarter the interest is at 9.0. Based on that we can calculate that during remaining 53 days it will total up to 22.0. Vor Biopharma expected interest is significantly lower compared to previous quarter (-48.8%) and same quarter last year (-46.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 27 | 20 -25.9% QoQ | 50 150.0% QoQ | 61 22.0% QoQ |
| 2020 | 34 25.9% YoY -44.3% QoQ | 35 75.0% YoY 2.9% QoQ | 68 36.0% YoY 94.3% QoQ | 41 -32.8% YoY -39.7% QoQ |
| 2021 | 213 526.5% YoY 419.5% QoQ | 89 154.3% YoY -58.2% QoQ | 70 2.9% YoY -21.3% QoQ | 48 17.1% YoY -31.4% QoQ |
| 2022 | 62 -70.9% YoY 29.2% QoQ | 42 -52.8% YoY -32.3% QoQ | 47 -32.9% YoY 11.9% QoQ | 62 29.2% YoY 31.9% QoQ |
| 2023 | 41 -33.9% YoY -33.9% QoQ | 38 -9.5% YoY -7.3% QoQ | 24 -48.9% YoY -36.8% QoQ | 43 -30.6% YoY 79.2% QoQ |
| 2024 | 9 -78.0% YoY -79.1% QoQ | - | - | - |
The average 5 years interest of Vor Biopharma was 4.32 per week. The last year interest of Vor Biopharma compared to the last 5 years has changed by -36.81%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -12.78%.
There is not enough data for Vor Biopharma Vor Biopharma stock to provide analysis
There is not enough data for Vor Biopharma Vor Biopharma stock to provide correlation calculation
There is not enough data for Vor Biopharma Vor Biopharma stock to provide analysis
There is not enough data for eHSC therapies to provide analysis
There is not enough data for eHSC therapies to provide correlation calculation
There is not enough data for eHSC therapies to provide analysis
There is not enough data for tremtelectogene empogeditemcel to provide analysis
There is not enough data for tremtelectogene empogeditemcel to provide correlation calculation
There is not enough data for tremtelectogene empogeditemcel to provide analysis
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. VOR33 expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 57 | 131 129.8% QoQ | 146 11.5% QoQ | 78 -46.6% QoQ |
| 2020 | 0 -100.0% YoY -100.0% QoQ | 162 23.7% YoY inf% QoQ | 22 -84.9% YoY -86.4% QoQ | 106 35.9% YoY 381.8% QoQ |
| 2021 | 183 inf% YoY 72.6% QoQ | 29 -82.1% YoY -84.2% QoQ | 42 90.9% YoY 44.8% QoQ | 105 -0.9% YoY 150.0% QoQ |
| 2022 | 97 -47.0% YoY -7.6% QoQ | 0 -100.0% YoY -100.0% QoQ | 72 71.4% YoY inf% QoQ | 115 9.5% YoY 59.7% QoQ |
| 2023 | 159 63.9% YoY 38.3% QoQ | 79 inf% YoY -50.3% QoQ | 54 -25.0% YoY -31.6% QoQ | 62 -46.1% YoY 14.8% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of VOR33 was 6.53 per week. The last year interest of VOR33 compared to the last 5 years has changed by -3.98%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -20.83%.
After 38 days of this quarter the interest is at 78.0. Based on that we can calculate that during remaining 53 days it will total up to 187.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 105 | 307 192.4% QoQ | 223 -27.4% QoQ | 231 3.6% QoQ |
| 2020 | 291 177.1% YoY 26.0% QoQ | 258 -16.0% YoY -11.3% QoQ | 266 19.3% YoY 3.1% QoQ | 232 0.4% YoY -12.8% QoQ |
| 2021 | 188 -35.4% YoY -19.0% QoQ | 297 15.1% YoY 58.0% QoQ | 291 9.4% YoY -2.0% QoQ | 308 32.8% YoY 5.8% QoQ |
| 2022 | 179 -4.8% YoY -41.9% QoQ | 351 18.2% YoY 96.1% QoQ | 251 -13.7% YoY -28.5% QoQ | 109 -64.6% YoY -56.6% QoQ |
| 2023 | 307 71.5% YoY 181.7% QoQ | 394 12.3% YoY 28.3% QoQ | 156 -37.8% YoY -60.4% QoQ | 204 87.2% YoY 30.8% QoQ |
| 2024 | 78 -74.6% YoY -61.8% QoQ | - | - | - |
The average 5 years interest of acute myeloid leukemia treatment was 19.33 per week. The last year interest of acute myeloid leukemia treatment compared to the last 5 years has changed by 4.86%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 2.43%.
After 39 days of this quarter the interest is at 24.0. Based on that we can calculate that during remaining 52 days it will total up to 56.0. hematological malignancies expected interest is significantly lower compared to previous quarter (-78.0%) and same quarter last year (-77.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 250 | 224 -10.4% QoQ | 156 -30.4% QoQ | 91 -41.7% QoQ |
| 2020 | 229 -8.4% YoY 151.6% QoQ | 187 -16.5% YoY -18.3% QoQ | 326 109.0% YoY 74.3% QoQ | 148 62.6% YoY -54.6% QoQ |
| 2021 | 268 17.0% YoY 81.1% QoQ | 361 93.0% YoY 34.7% QoQ | 264 -19.0% YoY -26.9% QoQ | 101 -31.8% YoY -61.7% QoQ |
| 2022 | 256 -4.5% YoY 153.5% QoQ | 100 -72.3% YoY -60.9% QoQ | 458 73.5% YoY 358.0% QoQ | 180 78.2% YoY -60.7% QoQ |
| 2023 | 250 -2.3% YoY 38.9% QoQ | 105 5.0% YoY -58.0% QoQ | 294 -35.8% YoY 180.0% QoQ | 254 41.1% YoY -13.6% QoQ |
| 2024 | 24 -90.4% YoY -90.6% QoQ | - | - | - |
The average 5 years interest of hematological malignancies was 17.34 per week. The last year interest of hematological malignancies compared to the last 5 years has changed by -4.96%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 5.91%.
After 38 days of this quarter the interest is at 78.0. Based on that we can calculate that during remaining 53 days it will total up to 187.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 236 | 476 101.7% QoQ | 298 -37.4% QoQ | 204 -31.5% QoQ |
| 2020 | 440 86.4% YoY 115.7% QoQ | 264 -44.5% YoY -40.0% QoQ | 203 -31.9% YoY -23.1% QoQ | 221 8.3% YoY 8.9% QoQ |
| 2021 | 236 -46.4% YoY 6.8% QoQ | 300 13.6% YoY 27.1% QoQ | 131 -35.5% YoY -56.3% QoQ | 164 -25.8% YoY 25.2% QoQ |
| 2022 | 145 -38.6% YoY -11.6% QoQ | 255 -15.0% YoY 75.9% QoQ | 253 93.1% YoY -0.8% QoQ | 171 4.3% YoY -32.4% QoQ |
| 2023 | 301 107.6% YoY 76.0% QoQ | 228 -10.6% YoY -24.3% QoQ | 269 6.3% YoY 18.0% QoQ | 304 77.8% YoY 13.0% QoQ |
| 2024 | 78 -74.1% YoY -74.3% QoQ | - | - | - |
The average 5 years interest of Mylotarg was 19.91 per week. The last year interest of Mylotarg compared to the last 5 years has changed by 7.23%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -20.07%.
There is not enough data for CD33-directed antibody drug conjugate therapy to provide analysis
There is not enough data for CD33-directed antibody drug conjugate therapy to provide correlation calculation
There is not enough data for CD33-directed antibody drug conjugate therapy to provide analysis
There is not enough data for VCAR33 to provide analysis
There is not enough data for VCAR33 to provide correlation calculation
There is not enough data for VCAR33 to provide analysis
After 38 days of this quarter the interest is at 188.0. Based on that we can calculate that during remaining 53 days it will total up to 450.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 224 | 354 58.0% QoQ | 439 24.0% QoQ | 355 -19.1% QoQ |
| 2020 | 391 74.6% YoY 10.1% QoQ | 319 -9.9% YoY -18.4% QoQ | 307 -30.1% YoY -3.8% QoQ | 257 -27.6% YoY -16.3% QoQ |
| 2021 | 308 -21.2% YoY 19.8% QoQ | 371 16.3% YoY 20.5% QoQ | 368 19.9% YoY -0.8% QoQ | 305 18.7% YoY -17.1% QoQ |
| 2022 | 588 90.9% YoY 92.8% QoQ | 494 33.2% YoY -16.0% QoQ | 533 44.8% YoY 7.9% QoQ | 517 69.5% YoY -3.0% QoQ |
| 2023 | 486 -17.3% YoY -6.0% QoQ | 581 17.6% YoY 19.5% QoQ | 462 -13.3% YoY -20.5% QoQ | 564 9.1% YoY 22.1% QoQ |
| 2024 | 188 -61.3% YoY -66.7% QoQ | - | - | - |
The average 5 years interest of CAR-T therapy was 32.35 per week. The last year interest of CAR-T therapy compared to the last 5 years has changed by 24.36%. The interest for CAR-T therapy is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 33.83%.
There is not enough data for trem-cel + VCAR33 treatment to provide analysis
There is not enough data for trem-cel + VCAR33 treatment to provide correlation calculation
There is not enough data for trem-cel + VCAR33 treatment to provide analysis
There is not enough data for CD33-CLL1 treatment to provide analysis
There is not enough data for CD33-CLL1 treatment to provide correlation calculation
There is not enough data for CD33-CLL1 treatment to provide analysis
There is not enough data for cGMP nucleases to provide analysis
There is not enough data for cGMP nucleases to provide correlation calculation
There is not enough data for cGMP nucleases to provide analysis
There is not enough data for Vor Biopharma headquarters. to provide analysis
There is not enough data for Vor Biopharma headquarters. to provide correlation calculation
There is not enough data for Vor Biopharma headquarters. to provide analysis